Ocular Information for Dopamine Level Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing Parkinson's disease, particularly those involving L-DOPA treatment, face challenges in real-time monitoring of dopamine levels, leading to motor complications like dyskinesia, as they rely on blood levodopa concentrations rather than brain levels, making it difficult to estimate the condition of patients accurately.
Innovation Solution
A method utilizing ocular information, such as blink parameters, to estimate the presence, amount, or level of dopamine or its equivalents in the brain, allowing for real-time monitoring and prediction of Parkinson's disease patient conditions through trained models that correlate ocular data with dopamine levels and treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If blood levodopa concentration is used to monitor treatment, then treatment management is simplified, but real-time brain dopamine level estimation is inaccurate
Solution Approach 1:
The patent uses ocular information (eye movement parameters, blink characteristics) as an intermediary indicator to indirectly estimate brain dopamine levels. Since direct brain measurement is invasive and complex, the patent identifies that ocular parameters serve as a non-invasive mediator that correlates with central dopamine activity, allowing clinicians to monitor treatment effectiveness without needing to directly measure brain chemistry.
2Measurement precision
If direct brain dopamine measurement is performed, then measurement accuracy is improved, but real-time monitoring becomes impractical
Solution Approach 1:
The patent replaces complex mechanical/invasive measurement systems (direct brain sampling, lumbar puncture, or specialized imaging equipment) with a simple optical observation system. By using standard video recording or eye-tracking technology to monitor ocular parameters, the patent achieves continuous real-time monitoring without requiring sophisticated medical equipment or invasive procedures.
3Reliability
If L-DOPA dosage is increased to maintain therapeutic effect, then dopamine replacement is improved, but risk of dyskinesia increases
Solution Approach 1:
The patent implements a feedback mechanism where ocular parameters are continuously monitored and used to adjust L-DOPA dosing in real-time. By establishing baseline ocular signatures for each patient and detecting deviations from this baseline, the system provides continuous feedback about the patient's dopamine status, enabling clinicians to optimize dosing to maintain therapeutic effectiveness while avoiding dyskinesia-inducing peaks.
Solution Approach 2:
The patent transitions from static, fixed dosing schedules to dynamic, adaptive dosing based on real-time ocular monitoring. The system allows dosing regimens to be continuously adjusted according to the patient's actual physiological state as reflected by ocular parameters, rather than relying on predetermined fixed doses, thereby optimizing the balance between therapeutic effect and side effect prevention.
Data Source
AI summary
The present disclosure provides methods of evaluating therapeutic or prophylactic agents or other medical technologies for patients with Parkinson's disease being treated with L-DOPA or L-DOPA-related compounds or dopamine agonists. Specifically, it provides a method of evaluating a therapeutic or prophylactic agent or other medical technology for a patient with Parkinson's disease who is being treated with L-DOPA or an L-DOPA-related compound or a dopamine agonist, including A) a step of obtaining ocular information of the patient, and B) a step of calculating an estimated effective amount or effective level of the therapeutic or prophylactic agent or other medical technology from the ocular information.